Kringle Pharma successfully raised 200 million JPY in funding from THVP-1 Fund (General Partner: Tohoku University Venture Partners Co., Ltd.).
June 1, 2018
Kringle’s recombinant human HGF is now available as a research reagent at REPROCELL, Inc. For more information, please contact REPROCELL, Inc. through their website as follows. https://www.reprocell.com/
May 11, 2018
Kringle Pharma announces that the last subject has completed the follow-up period after dosing in the Phase I/II study of recombinant human HGF for acute spinal cord injury.
February 27, 2018
A patent entitled 'HGF preparation suitable for treatment of nervous diseases' was granted in Japan. Patent No. JP6281992.
January 10, 2018
Clinical data from the investigator-initiated Phase I/II of recombinant human HGF for treatment of vocal fold scar were published in Journal of Tissue Engineering and Regenerative Medicine (25 DEC 2017, DOI: 10.1002/term.2603). It was demonstrated that intracordal injection of the recombinant human HGF drug was safe, feasible, and potentially effective for vocal fold scar patients based on several evaluation methods.
Copyright (C)2004-2011 Kringle Pharma, Inc. All rights reserved.